QI
NBIX icon

QS Investors’s Neurocrine Biosciences NBIX Stock Holding History

QS Investors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$201K Sell
2,058
-300
-13% -$28.8K ﹤0.01% 1066
2021
Q1 		$230K Hold
2,358
– – ﹤0.01% 1069
2020
Q4 		$226K Buy
2,358
+257
+12% +$24.8K ﹤0.01% 1080
2020
Q3 		$203K Hold
2,101
– – ﹤0.01% 1071
2020
Q2 		$257K Sell
2,101
-425
-17% -$47K ﹤0.01% 1077
2020
Q1 		$219K Buy
2,526
+185
+8% +$18.1K ﹤0.01% 1040
2019
Q4 		$254K Sell
2,341
-240
-9% -$25.1K ﹤0.01% 1135
2019
Q3 		$233K Buy
2,581
+240
+10% +$22.4K ﹤0.01% 1167
2019
Q2 		$198K Hold
2,341
– – ﹤0.01% 1222
2019
Q1 		$207K Sell
2,341
-9
-0.4% -$752 ﹤0.01% 1210
2018
Q4 		$168K Hold
2,350
– – ﹤0.01% 1183
2018
Q3 		$289K Hold
2,350
– – ﹤0.01% 1102
2018
Q2 		$231K Hold
2,350
– – ﹤0.01% 1165
2018
Q1 		$195K Hold
2,350
– – ﹤0.01% 1184
2017
Q4 		$182K Buy
2,350
+341
+17% +$23.3K ﹤0.01% 1244
2017
Q3 		$123K Hold
2,009
– – ﹤0.01% 1377
2017
Q2 		$92K Hold
2,009
– – ﹤0.01% 1399
2017
Q1 		$87K Buy
2,009
+2,000
+22,222% +$85.7K ﹤0.01% 1412
2016
Q4 		$1K Hold
9
– – ﹤0.01% 1674
2016
Q3 		$1K Hold
9
– – ﹤0.01% 1664
2016
Q2 		$1K Sell
9
-136,502
-100% -$6.28M ﹤0.01% 1707
2016
Q1 		$5.4M Hold
136,511
– – 0.05% 358
2015
Q4 		$7.72M Buy
136,511
+10,359
+8% +$526K 0.07% 244
2015
Q3 		$5.02M Sell
126,152
-200
-0.2% -$9.67K 0.05% 357
2015
Q2 		$6.04M Hold
126,352
– – 0.07% 321
2015
Q1 		$5.02M Hold
126,352
– – 0.06% 376
2014
Q4 		$2.82M Buy
+126,352
New +$2.39M 0.03% 510

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return

QS Investors's NBIX Position: Q2 2021 in Review

QS Investors reduced its Neurocrine Biosciences (NBIX) stake by 13% in Q2 2021, selling an estimated $28.8K and leaving 2,058 shares worth $201K. The position accounts for ﹤0.01% of the portfolio, ranked #1066.

QS Investors first reported a position in NBIX in Q4 2014 and has held it in 27 quarters since. The position peaked at $7.72M in Q4 2015. 408 funds tracked by Wall St. Rank hold NBIX as of Q2 2021.

  • QS Investors held 2,058 shares of Neurocrine Biosciences worth $201K as of Q2 2021.
  • QS Investors sold 300 Neurocrine Biosciences shares in Q2 2021, an estimated $28.8K.
  • Neurocrine Biosciences made up ﹤0.01% of QS Investors's portfolio in Q2 2021, its #1066 holding.
  • QS Investors first reported a position in Neurocrine Biosciences in Q4 2014 and has held it in 27 quarters since.
  • QS Investors's Neurocrine Biosciences position peaked at $7.72M in Q4 2015.
  • 408 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.